Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: Challenges and future perspectives
L Ascione, G Castellano, G Curigliano… - Current Opinion in …, 2024 - journals.lww.com
More recently, oral SERDs have been tested in patients with early hormone receptor positive
breast cancer, although their impact on survival and in this curative setting compared to …
breast cancer, although their impact on survival and in this curative setting compared to …
[HTML][HTML] New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment
C Amaral, CF Almeida, MJ Valente, CL Varela… - Cancers, 2025 - mdpi.com
Abstract Background/Objectives: Endocrine therapies that comprise anti-estrogens and
aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive …
aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive …